Skip to main content
Terug
Watch Compare

EUPRAXIA PHARMACEUTICALS INC.

Datakwaliteit: 100%
EPRX
Nasdaq Manufacturing Chemicals
€ 6,86
▼ € 0,22 (-3,11%)
Marktkapitalisatie: 421,91 M
Prijs
€ 6,86
Marktkapitalisatie
421,91 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -28,55 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-66,83%
Onder sectorgemiddelde (-53,53%)
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio15,12
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-10,94 | -10,68
Onder sectorgemiddelde (-1,48)
P/B Ratio5,14
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -10,9 -1,5
P/B 5,1 1,6
ROE % -66,8 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

7 analisten
Buy
Huidig
€ 6,86
+109.8%
Koersdoel
€ 14,39
€ 11,00
€ 14,00
€ 19,00
Vooruitzicht
Forward K/W -10,68
Forward WPA -€ 0,64
Omzet Sch. 15,91 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,64
-€ 1,04 – € 0,36
 15,91 M 8
FY2026 -€ 0,72
-€ 0,96 – -€ 0,50
 0,0 9

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,16 -€ 0,37 -133,3%
Q32025 -€ 0,19 -€ 0,19 +1,0%
Q22025 -€ 0,19 -€ 0,26 -40,5%
Q12025 -€ 0,17 -€ 0,21 -26,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -38,58 M
ROE -66,83% ROA -63,71%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -28,55 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 15,12
Interest Coverage N/A Asset Turnover 0,00
Working Capital 79,47 M Tangible Book Value 82,04 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10,94 Forward P/E -10,68
P/B Ratio 5,14 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 26,52 Fwd Earnings Yield N/A
FCF Yield -6,77%
Market Cap 421,91 M Enterprise Value 341,35 M
Per Share
EPS (Diluted TTM) -1,03 Revenue / Share 0,00
FCF / Share -0,46 OCF / Share -0,46
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 74,02%
SBC-Adj. FCF -37,31 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 0,0 0,0 0,0
Net Income -38,58 M -25,50 M -28,22 M
EPS (Diluted) -1,03 -0,76 -1,17
Gross Profit — — —
Operating Income — — —
EBITDA — — —
R&D Expenses 21,33 M 16,08 M 20,56 M
SG&A Expenses — — —
D&A — — —
Interest Expense 0,0 603.573,0 1,17 M
Income Tax 19.091,0 1.804,0 36.423,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 86,15 M 34,94 M 20,27 M
Total Liabilities 5,70 M 3,10 M 19,37 M
Shareholders' Equity 82,04 M 33,40 M 2,22 M
Total Debt — — —
Cash & Equivalents 80,56 M 33,10 M 19,34 M
Current Assets 85,10 M 34,44 M 19,80 M
Current Liabilities 5,63 M 3,10 M 19,37 M